By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Resverlogix Corporation 

279 Midpark Way SE
Suite 202
Calgary  Alberta  T2X 1M2  Canada
Phone: 403-254-9252 Fax: 403-256-8495


SEARCH JOBS








Company News
Resverlogix Corporation (RVX.TO) Closes Additional $30 Million From Citibank Loan 8/18/2014 8:09:14 AM
Resverlogix Corporation (RVX.TO) Shareholders Approve Additional $30 Million From Citibank Loan 8/14/2014 8:31:24 AM
Resverlogix Corporation (RVX.TO) Release: RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly In Patients With Diabetes Mellitus 7/23/2014 12:33:23 PM
Resverlogix Corporation (RVX.TO) Secures An Additional $30 Million From Citibank Loan 7/7/2014 8:43:28 AM
Resverlogix Corporation (RVX.TO) Release: Leading Life Science Publication SciBX Highlights RVX-208 5/21/2014 10:08:53 AM
Resverlogix Corporation (RVX.TO) Conference Call & Webcast Announcement 2/7/2014 6:22:43 AM
Resverlogix Corporation (RVX.TO) Announces Combined RVX-208 Findings From SUSTAIN & ASSURE Phase 2b Trials 1/16/2014 9:08:25 AM
Resverlogix Corporation (RVX.TO) Completes Enrollment Of Phase 2 Clinical Trial Of RVX-208 In Patients With Pre-Diabetes Mellitus 12/23/2013 9:57:33 AM
Resverlogix Corporation (RVX.TO) Announces Two New Findings From the ASSURE Trial Relating to Inflammation and Plaque Vulnerability 11/4/2013 10:12:53 AM
Resverlogix Corporation (RVX.TO) Release: Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis 9/3/2013 10:37:01 AM
12345678910...
//-->